Invivyd (IVVD) awards CSO stock options for 625,000 shares at $1.85

Rhea-AI Filing Summary

Invivyd, Inc. granted a large stock option award to its Chief Scientific Officer. On January 29, 2026, Allen Robert D. III received a stock option covering 625,000 shares of Invivyd common stock at an exercise price of $1.85 per share.

The option vests over three years, with 1/36th of the shares vesting in substantially equal monthly installments starting one month after the grant date, conditioned on his continued service on each vesting date. Following this grant, he beneficially owns 625,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Allen Robert D. III

Role Chief Scientific Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	625,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 625,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allen Robert D. III

(Last) (First) (Middle)

C/O INVIVYD, INC.

209 CHURCH STREET

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Invivyd, Inc. [ IVVD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.85	01/29/2026		A		625,000		(1)	01/28/2036	Common Stock	625,000	$0.00	625,000	D

Explanation of Responses:

1. This option vests over a three-year period, with 1/36th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date of January 29, 2026, subject to the Reporting Person's continuous service as of each vesting date.

	/s/ Jill Andersen attorney-in-fact for Robert D. Allen III	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Invivyd (IVVD) report for January 29, 2026?

Invivyd reported a stock option grant to Chief Scientific Officer Allen Robert D. III. He received options for 625,000 shares of common stock, granted on January 29, 2026, as disclosed in a Form 4 insider filing with the SEC.

How many Invivyd (IVVD) shares are covered by the new option grant?

The new option grant covers 625,000 shares of Invivyd common stock. These shares are underlying a single stock option award reported as a derivative security, with all 625,000 derivative securities beneficially owned directly after the transaction.

What is the exercise price of the stock option granted by Invivyd (IVVD)?

The stock option granted to the Chief Scientific Officer has an exercise price of $1.85 per share. This is the price at which he can purchase Invivyd common stock upon exercising vested portions of the option in the future.

How does the Invivyd (IVVD) stock option for the CSO vest over time?

The option vests over three years in monthly installments. Specifically, 1/36th of the shares subject to the option vest in substantially equal monthly installments, starting one month after January 29, 2026, if he remains in continuous service on each vesting date.

Who is the Invivyd (IVVD) insider involved in this Form 4 filing?

The insider is Allen Robert D. III, Invivyd’s Chief Scientific Officer. He is reported as an officer, not a director or 10% owner, and he now beneficially owns 625,000 derivative securities directly through this stock option grant.

Is the reported Invivyd (IVVD) transaction a purchase or a grant of options?

The reported transaction is a grant of stock options, not an open-market share purchase. The Form 4 shows a derivative security transaction coded as an acquisition (A) of a Stock Option (Right to Buy) covering 625,000 shares of common stock.